Neurological Surgery 脳神経外科51巻5号

2023年09月発行

特集 臨床脳神経外科医にとってのWHO脳腫瘍分類第5版 Ⅱ 成人悪性脳腫瘍

星細胞腫，IDH変異型

著者： 有田英之¹

所属機関： ¹大阪国際がんセンター脳神経外科

ページ範囲：P.800 - P.810

Point
・WHO脳腫瘍分類の改訂により，星細胞腫，IDH変異型の定義が変更され，以前より臨床的に明確な腫瘍の一群となった．
・星細胞腫，IDH変異型は治療において，手術による摘出の重要性が明確になってきている．
・分子分類導入に伴い，疾患分類が変更になったことを踏まえて，治療のエビデンスを再考する必要がある．

参考文献

1）Banan R, et al：Infratentorial IDH-mutant astrocytoma is a distinct subtype. Acta Neuropathol 140：569-581, 2020

2）WHO Classification of Tumours Editorial Board：WHO Classification of Tumours, 5th ed, vol. 6. Central Nervous System Tumours. IARC, Lyon, 2021

3）Shirahata M, et al：Novel, improved grading system（s）for IDH-mutant astrocytic gliomas. Acta Neuropathol 136：153-166, 2018

4）Brat DJ, et al：cIMPACT-NOW update 5：recommended grading criteria and terminologies for IDH-mutant astrocytomas. Acta Neuropathol 139：603-608, 2020

mutant glioblastoma from a distinct cell of origin. J Clin Oncol 29：4482-4490, 2011

6）Patel SH, et al：T2-FLAIR mismatch, an imaging biomarker for IDH and 1p/19q status in lower-grade gliomas：a TCGA/TCIA project. Clin Cancer Res 23：6078-6085, 2017

7）Jain R, et al：“Real world” use of a highly reliable imaging sign：“T2-FLAIR mismatch” for identification of IDH mutant astrocytomas. Neuro Oncol 22：936-943, 2020

-mutant, non-CODEL astrocytomas. Front Oncol 10：596448, 2021　doi:10.3389/fonc.2020.596448

9）Wagner MW, et al：T2-FLAIR mismatch sign in pediatric low-grade glioma. AJNR Am J Neuroradiol 44：841-845, 2023

10）Karschnia P, et al：Evidence-based recommendations on categories for extent of resection in diffuse glioma. Eur J Cancer 149：23-33, 2021

11）Jakola AS, et al：Surgical resection versus watchful waiting in low-grade gliomas. Ann Oncol 28：1942-1948, 2017

-mutant WHO grade 2 gliomas：a retrospective population-based parallel cohort study. J Neurosurg 137：1321-1328, 2022

13）Smith JS, et al：Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J Clin Oncol 26：1338-1345, 2008

14）Wijnenga MMJ, et al：The impact of surgery in molecularly defined low-grade glioma：an integrated clinical, radiological, and molecular analysis. Neuro Oncol 20：103-112, 2018

15）Kavouridis VK, et al：Contemporary assessment of extent of resection in molecularly defined categories of diffuse low-grade glioma：a volumetric analysis. J Neurosurg 133：1291-1301, 2020

16）Yordanova YN, et al：Awake surgery for WHO Grade Ⅱ gliomas within “noneloquent” areas in the left dominant hemisphere：toward a “supratotal” resection. Clinical article. J Neurosurg 115：232-239, 2011

17）Rossi M, et al：Association of supratotal resection with progression-free survival, malignant transformation, and overall survival in lower-grade gliomas. Neuro Oncol 23：812-826, 2021

18）Karim AB, et al：A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma：European Organization for Research and Treatment of Cancer（EORTC）Study 22844. Int J Radiat Oncol Biol Phys 36：549-556, 1996

19）van den Bent MJ, et al；EORTC Radiotherapy and Brain Tumor Groups and the UK Medical Research Council：Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults：the EORTC 22845 randomised trial. Lancet 366：985-990, 2005

20）Breen WG, et al：Final report from Intergroup NCCTG 86-72-51（Alliance）：a phase Ⅲ randomized clinical trial of high-dose versus low-dose radiation for adult low-grade glioma. Neuro Oncol 22：830-837, 2020

21）Weller M, et al：EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol 18：170-186, 2021

22）Baumert BG, et al：Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma（EORTC 22033-26033）：a randomised, open-label, phase 3 intergroup study. Lancet Oncol 17：1521-1532, 2016

23）Buckner JC, et al：Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma. N Engl J Med 374：1344-1355, 2016

24）Fisher BJ, et al：Phase 2 study of temozolomide-based chemoradiation therapy for high-risk low-grade gliomas：preliminary results of Radiation Therapy Oncology Group 0424. Int J Radiat Oncol Biol Phys 91：497-504, 2015

25）Kessler T, et al：Conventional and emerging treatments of astrocytomas and oligodendrogliomas. J Neurooncol 162：471-478, 2023

26）van den Bent MJ, et al：Interim results from the CATNON trial（EORTC study 26053-22054）of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma：a phase 3, randomised, open-label intergroup study. Lancet 390：1645-1653, 2017

27）van den Bent MJ, et al：Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma（CATNON；EORTC study 26053-22054）：second interim analysis of a randomised, open-label, phase 3 study. Lancet Oncol 22：813-823, 2021

28）Mellinghoff IK, et al：Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma：a randomized, perioperative phase 1 trial. Nat Med 29：615-622, 2023

29）Mellinghoff IK, et al：Vorasidenib in IDH1- or IDH2-mutant low-grade glioma. N Engl J Med 389：589-601, 2023

30）van den Bent MJ, et al：Bevacizumab and temozolomide in patients with first recurrence of WHO grade Ⅱ and Ⅲ glioma, without 1p/19q co-deletion（TAVAREC）：a randomised controlled phase 2 EORTC trial. Lancet Oncol 19：1170-1179, 2018

31）Suzuki H, et al：Mutational landscape and clonal architecture in grade Ⅱ and Ⅲ gliomas. Nat Genet 47：458-468, 2015

32）Olar A, et al：IDH mutation status and role of WHO grade and mitotic index in overall survival in grade Ⅱ-Ⅲ diffuse gliomas. Acta Neuropathol 129：585-596, 2015

33）Yoda RA, et al：Mitotic index thresholds do not predict clinical outcome for IDH-mutant astrocytoma. J Neuropathol Exp Neurol 78：1002-1010, 2019

-mutant gliomas. Neuro Oncol 21：1519-1528, 2019

35）Kros JM, et al：Mitotic count is prognostic in IDH-mutant astrocytoma without homozygous deletion of CDKN2A/B. Results of consensus panel review of EORTC trials 26053 and EORTC 22033-26033. Neuro Oncol noac282, 2022　doi:10.1093/neuonc/noac282

36）Tesileanu CMS, et al：Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma. Neuro Oncol 23：1547-1559, 2021

37）Aoki K, et al：Prognostic relevance of genetic alterations in diffuse lower-grade gliomas. Neuro Oncol 20：66-77, 2018

38）Yang RR, et al：IDH mutant lower grade（WHO Grades Ⅱ/Ⅲ）astrocytomas can be stratified for risk by CDKN2A, CDK4 and PDGFRA copy number alterations. Brain Pathol 30：541-553, 2020

-mutant glioblastomas with distinct epigenetic and copy number alterations and stratified clinical risks. Neurooncol Adv 1：vdz015, 2019　doi:10.1093/noajnl/vdz015

40）Draaisma K, et al：PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients. Acta Neuropathol Commun 3：88, 2015　doi:10.1186/s40478-015-0265-4

41）Ceccarelli M, et al；TCGA Research Network：Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell 164：550-563, 2016

42）Bell EH, et al：Comprehensive genomic analysis in NRG Oncology/RTOG 9802：a phase Ⅲ trial of radiation versus radiation plus procarbazine, lomustine（CCNU）, and vincristine in high-risk low-grade glioma. J Clin Oncol 38：3407-3417, 2020

43）Pignatti F, et al；European Organization for Research and Treatment of Cancer Brain Tumor Cooperative Group；European Organization for Research and Treatment of Cancer Radiotherapy Cooperative Group：Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol 20：2076-2084, 2002

44）Chang EF, et al：Multiinstitutional validation of the University of California at San Francisco Low-Grade Glioma Prognostic Scoring System. Clinical article. J Neurosurg 111：203-210, 2009

45）Brat DJ, et al：cIMPACT-NOW update 3：recommended diagnostic criteria for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade Ⅳ”. Acta Neuropathol 136：805-810, 2018

46）Reuss DE, et al：Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities. Acta Neuropathol 130：407-417, 2015

-wildtype diffuse astrocytic glioma with molecular features of glioblastoma. Acta Neuropathol 142：323-338, 2021